Top

Current Heart Failure Reports

Published in:

Open Access 02-05-2024 | Heart Failure | Review

Relevance of Cardiovascular Exercise in Cancer and Cancer Therapy-Related Cardiac Dysfunction

Authors: Simon Wernhart, Tienush Rassaf

Published in: Current Heart Failure Reports | Issue 3/2024

Abstract

Purpose of the Review

Cancer therapy-related cardiac dysfunction (CTRCD) has been identified as a threat to overall and cancer-related survival. Although aerobic exercise training (AET) has been shown to improve cardiorespiratory fitness (CRF), the relationship between specific exercise regimens and cancer survival, heart failure development, and reduction of CTRCD is unclear. In this review, we discuss the impact of AET on molecular pathways and the current literature of sports in the field of cardio-oncology.

Recent Findings

Cardio-oncological exercise trials have focused on variations of AET intensity by using moderate continuous and high intensity interval training, which are applicable, safe, and effective approaches to improve CRF.

Summary

AET increases CRF, reduces cardiovascular morbidity and heart failure hospitalization and should thus be implemented as an adjunct to standard cancer therapy, although its long-term effect on CTRCD remains unknown. Despite modulating diverse molecular pathways, it remains unknown which exercise regimen, including variations of AET duration and frequency, is most suited to facilitate peripheral and central adaptations to exercise and improve survival in cancer patients.

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.CrossRefPubMed

WHO: Cancer Key Facts. https://www.who.int/news-room/fact-sheets/detail/cancer (2022). Accessed 29 Mar 2024.

Finke D, Heckmann MB, Wilhelm S, Entenmann L, Hund H, Bougatf N, et al. Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients-a large monocenter cohort study. Clin Res Cardiol. 2023;112(2):203–14. https://doi.org/10.1007/s00392-022-02001-6.CrossRefPubMed

Hurria A, Jones L, Muss HB. Cancer treatment as an accelerated aging process: assessment, biomarkers, and interventions. Am Soc Clin Oncol Educ Book. 2016;35:e516–22. https://doi.org/10.1200/edbk_156160.CrossRefPubMed

Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA. 2009;301(19):2024–35. https://doi.org/10.1001/jama.2009.681.CrossRefPubMed

Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity, risk of death and recurrence in breast cancer survivors: a systematic review and meta-analysis of epidemiological studies. Acta Oncol. 2015;54(5):635–54. https://doi.org/10.3109/0284186x.2014.998275.CrossRefPubMed

Zheng C, Beresford SA, Van Horn L, Tinker LF, Thomson CA, Neuhouser ML, et al. Simultaneous association of total energy consumption and activity-related energy expenditure with risks of cardiovascular disease, cancer, and diabetes among postmenopausal women. Am J Epidemiol. 2014;180(5):526–35. https://doi.org/10.1093/aje/kwu152.CrossRefPubMedPubMedCentral

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. https://doi.org/10.1093/eurheartj/ehac244.CrossRefPubMed

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. https://doi.org/10.1093/eurheartj/ehab368.CrossRefPubMed

10.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–39. https://doi.org/10.1093/eurheartj/ehad195.CrossRefPubMed

11.

Xue K, Gu JJ, Zhang Q, Liu X, Wang J, Li XQ, et al. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial. Oncotarget. 2016;7(22):32519–31. https://doi.org/10.18632/oncotarget.8685.CrossRefPubMedPubMedCentral

12.

Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910–6. https://doi.org/10.1200/jco.2009.27.3615.CrossRefPubMed

13.

Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol. 2017;35(8):878–84. https://doi.org/10.1200/jco.2015.65.7916.CrossRefPubMed

14.•

Paterson DI, Wiebe N, Cheung WY, Mackey JR, Pituskin E, Reiman A, et al. Incident cardiovascular disease among adults with cancer: a population-based cohort study. JACC CardioOncol. 2022;4(1):85–94. https://doi.org/10.1016/j.jaccao.2022.01.100. This large study illustrates that a diagnosis of cancer is independently associated with increased risk for cardiovascular death.CrossRefPubMedPubMedCentral

15.

Totzeck M, Mincu RI, Heusch G, Rassaf T. Heart failure from cancer therapy: can we prevent it? ESC Heart Fail. 2019;6(4):856–62. https://doi.org/10.1002/ehf2.12493.CrossRefPubMedPubMedCentral

16.

Totzeck M, Mincu RI, Mrotzek S, Schadendorf D, Rassaf T. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol. 2018;25(5):482–94. https://doi.org/10.1177/2047487318755193.CrossRefPubMed

17.

Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients. J Am Heart Assoc. 2017;6(8). https://doi.org/10.1161/jaha.117.006278.

18.

Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280:163–75. https://doi.org/10.1016/j.ijcard.2019.01.038.CrossRefPubMed

19.

Ramin C, Schaeffer ML, Zheng Z, Connor AE, Hoffman-Bolton J, Lau B, et al. All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort. J Natl Cancer Inst. 2021;113(2):137–45. https://doi.org/10.1093/jnci/djaa096.CrossRefPubMed

20.

Santoro F, Tarantino N, Pellegrino PL, Caivano M, Lopizzo A, Di Biase M, et al. Cardiovascular sequelae of radiation therapy. Clin Res Cardiol. 2014;103(12):955–67. https://doi.org/10.1007/s00392-014-0718-y.CrossRefPubMed

21.

Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911. https://doi.org/10.1200/jco.2016.70.5400.CrossRefPubMed

22.

Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer therapy-related cardiac dysfunction and heart failure: Part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail. 2016;9(1):e002661. https://doi.org/10.1161/circheartfailure.115.002661.CrossRefPubMedPubMedCentral

23.

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8. https://doi.org/10.1161/circulationaha.114.013777.CrossRefPubMed

24.

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801. https://doi.org/10.1093/eurheartj/ehw211.CrossRefPubMed

25.

Laufer-Perl M, Arnold JH, Mor L, Amrami N, Derakhshesh M, Moshkovits Y, et al. The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy. Clin Res Cardiol. 2020;109(2):255–62. https://doi.org/10.1007/s00392-019-01508-9.CrossRefPubMed

26.

Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22(2):350–61. https://doi.org/10.1002/ejhf.1631.CrossRefPubMed

27.

Michel L, Mincu RI, Mrotzek SM, Korste S, Neudorf U, Rassaf T, et al. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis. ESC Heart Fail. 2020;7(2):423–33. https://doi.org/10.1002/ehf2.12589.CrossRefPubMedPubMedCentral

28.

Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis. 2018;10(Suppl 35):S4282-s95. https://doi.org/10.21037/jtd.2018.08.15.CrossRefPubMedPubMedCentral

29.

Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015;101(23):1874–80. https://doi.org/10.1136/heartjnl-2015-307848.CrossRefPubMed

30.

López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720–9. https://doi.org/10.1093/eurheartj/ehaa006.CrossRefPubMed

31.

Mousavi N, Tan TC, Ali M, Halpern EF, Wang L, Scherrer-Crosbie M. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50–59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging. 2015;16(9):977–84. https://doi.org/10.1093/ehjci/jev113.CrossRefPubMed

32.

Thavendiranathan P, Negishi T, Coté MA, Penicka M, Massey R, Cho GY, et al. Single versus standard multiview assessment of global longitudinal strain for the diagnosis of cardiotoxicity during cancer therapy. JACC Cardiovasc Imaging. 2018;11(8):1109–18. https://doi.org/10.1016/j.jcmg.2018.03.003.CrossRefPubMed

33.

Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol. 2019;4(10):1007–18. https://doi.org/10.1001/jamacardio.2019.2952.CrossRefPubMedPubMedCentral

34.

Sae Jang KJR, Charles L. Loprinzi, Saro Armenian, Daniel John Lenihan, Joerg Herrmann. Systematic review and meta-analysis of definitions and reported incidences of anthracycline cardiotoxicity. 2019 ASCO Annual Meeting: J Clin Oncol 2019; e:23081. https://doi.org/10.1200/JCO.2019.37.15_suppl.e23081.

35.

Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287–306. https://doi.org/10.1016/j.mayocp.2014.05.013.CrossRefPubMed

36.

Ohtani K, Fujino T, Ide T, Funakoshi K, Sakamoto I, Hiasa KI, et al. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity. Clin Res Cardiol. 2019;108(6):600–11. https://doi.org/10.1007/s00392-018-1386-0.CrossRefPubMed

37.

Ohtani K, Ide T, Hiasa KI, Sakamoto I, Yamashita N, Kubo M, et al. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity. Clin Res Cardiol. 2019;108(10):1128–39. https://doi.org/10.1007/s00392-019-01448-4.CrossRefPubMed

38.

Yoon HJ, Kim KH, Kim HY, Park H, Cho JY, Hong YJ, et al. Impacts of non-recovery of trastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer. Clin Res Cardiol. 2019;108(8):892–900. https://doi.org/10.1007/s00392-019-01417-x.CrossRefPubMed

39.

Fornaro A, Olivotto I, Rigacci L, Ciaccheri M, Tomberli B, Ferrantini C, et al. Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience. Eur J Heart Fail. 2018;20(5):898–906. https://doi.org/10.1002/ejhf.1049.CrossRefPubMed

40.

Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–79. https://doi.org/10.1002/cncr.11407.CrossRefPubMed

41.

Squires RW, Shultz AM, Herrmann J. Exercise training and cardiovascular health in cancer patients. Curr Oncol Rep. 2018;20(3):27. https://doi.org/10.1007/s11912-018-0681-2.CrossRefPubMed

42.

Fardman A, Banschick GD, Rabia R, Percik R, Fourey D, Segev S, et al. Cardiorespiratory fitness and survival following cancer diagnosis. Eur J Prev Cardiol. 2021;28(11):1242–9. https://doi.org/10.1177/2047487320930873.CrossRefPubMed

43.•

Groarke JD, Payne DL, Claggett B, Mehra MR, Gong J, Caron J, et al. Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer. Eur Heart J Qual Care Clin Outcomes. 2020;6(4):315–22. https://doi.org/10.1093/ehjqcco/qcaa015. This work clearly illustrates the inverse association of cardiopulmonary fitness and all-cause mortality in cancer patients.CrossRefPubMedPubMedCentral

44.

Okwuosa TM, Ray RM, Palomo A, Foraker RE, Johnson L, Paskett ED, et al. Pre-diagnosis exercise and cardiovascular events in primary breast cancer: women’s health initiative. JACC CardioOncol. 2019;1(1):41–50. https://doi.org/10.1016/j.jaccao.2019.08.014.CrossRefPubMedPubMedCentral

45.

Nagy AC, GulAcsi BP, CserEp Z, Hangody L, Forster T. Late cardiac effect of anthracycline therapy in physically active breast cancer survivors - a prospective study. Neoplasma. 2017;64(1):92–100. https://doi.org/10.4149/neo_2017_111.CrossRefPubMed

46.

Murray J, Bennett H, Bezak E, Perry R. The role of exercise in the prevention of cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy: systematic review. Eur J Prev Cardiol. 2022;29(3):463–72. https://doi.org/10.1093/eurjpc/zwab006.CrossRefPubMed

47.

Foulkes SJ, Howden EJ, Bigaran A, Janssens K, Antill Y, Loi S, et al. Persistent impairment in cardiopulmonary fitness after breast cancer chemotherapy. Med Sci Sports Exerc. 2019;51(8):1573–81. https://doi.org/10.1249/mss.0000000000001970.CrossRefPubMed

48.

Howden EJ, Bigaran A, Beaudry R, Fraser S, Selig S, Foulkes S, et al. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. Eur J Prev Cardiol. 2019;26(3):305–15. https://doi.org/10.1177/2047487318811181.CrossRefPubMed

49.

Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular toxicity in cancer. Circulation. 2018;137(11):1176–91. https://doi.org/10.1161/circulationaha.117.024671.CrossRefPubMedPubMedCentral

50.•

Antunes P, Joaquim A, Sampaio F, Nunes C, Ascensão A, Vilela E, et al. Effects of exercise training on cardiac toxicity markers in women with breast cancer undergoing chemotherapy with anthracyclines: a randomized controlled trial. Eur J Prev Cardiol. 2023;30(9):844–55. https://doi.org/10.1093/eurjpc/zwad063. Compared to usual care, exercise training increased peak oxygen consumption during and after chemotherapy, but established markers of cardiotoxicity did not change in this short-term follow-up.CrossRefPubMed

51.

Wonisch M, Hofmann P, Fruhwald FM, Kraxner W, Hödl R, Pokan R, et al. Influence of beta-blocker use on percentage of target heart rate exercise prescription. Eur J Cardiovasc Prev Rehabil. 2003;10(4):296–301. https://doi.org/10.1097/00149831-200308000-00013.CrossRefPubMed

52.

Hofmann P, Von Duvillard SP, Seibert FJ, Pokan R, Wonisch M, Lemura LM, et al. %HRmax target heart rate is dependent on heart rate performance curve deflection. Med Sci Sports Exerc. 2001;33(10):1726–31. https://doi.org/10.1097/00005768-200110000-00017.CrossRefPubMed

53.

Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J. 2018;39(14):1144–61. https://doi.org/10.1093/eurheartj/ehw180.CrossRefPubMed

54.

Guazzi M, Wilhelm M, Halle M, Van Craenenbroeck E, Kemps H, de Boer RA, et al. Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy - a clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology. Eur J Heart Fail. 2022;24(8):1327–45. https://doi.org/10.1002/ejhf.2601.CrossRefPubMed

55.

Malhotra R, Bakken K, D’Elia E, Lewis GD. Cardiopulmonary exercise testing in heart failure. JACC Heart Fail. 2016;4(8):607–16. https://doi.org/10.1016/j.jchf.2016.03.022.CrossRefPubMed

56.

West MA, Lythgoe D, Barben CP, Noble L, Kemp GJ, Jack S, et al. Cardiopulmonary exercise variables are associated with postoperative morbidity after major colonic surgery: a prospective blinded observational study. Br J Anaesth. 2014;112(4):665–71. https://doi.org/10.1093/bja/aet408.CrossRefPubMed

57.

West MA, Parry MG, Lythgoe D, Barben CP, Kemp GJ, Grocott MP, et al. Cardiopulmonary exercise testing for the prediction of morbidity risk after rectal cancer surgery. Br J Surg. 2014;101(9):1166–72. https://doi.org/10.1002/bjs.9551.CrossRefPubMed

58.

Ha D, Mazzone PJ, Ries AL, Malhotra A, Fuster M. The utility of exercise testing in patients with lung cancer. J Thorac Oncol. 2016;11(9):1397–410. https://doi.org/10.1016/j.jtho.2016.04.021.CrossRefPubMedPubMedCentral

59.

Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377–81.CrossRefPubMed

60.

D’Ascenzi F, Anselmi F, Fiorentini C, Mannucci R, Bonifazi M, Mondillo S. The benefits of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology. Eur J Prev Cardiol. 2021;28(7):725–35. https://doi.org/10.1177/2047487319874900.CrossRefPubMed

61.

Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle. 2015;6(2):115–24. https://doi.org/10.1002/jcsm.12042.CrossRefPubMedPubMedCentral

62.

Karvonen J, Vuorimaa T. Heart rate and exercise intensity during sports activities. Practical application Sports Med. 1988;5(5):303–11. https://doi.org/10.2165/00007256-198805050-00002.CrossRefPubMed

63.

Michalski M, Rowed K, Lavery JA, Moskowitz CS, Capaci C, Stene G, et al. Validity of estimated cardiorespiratory fitness in patients with primary breast cancer. JACC CardioOncol. 2022;4(2):210–9. https://doi.org/10.1016/j.jaccao.2022.05.003.CrossRefPubMedPubMedCentral

64.

Wernhart S, Mincu R, Balcer B, Rammos C, Muentjes C, Rassaf T. The cardiorespiratory optimal point as a discriminator of lesion severity in adults with congenital heart disease. J Sports Med Phys Fitness. 2023;63(8):941–8. https://doi.org/10.23736/s0022-4707.23.14835-3.CrossRefPubMed

65.•

Foulkes SJ, Howden EJ, Haykowsky MJ, Antill Y, Salim A, Nightingale SS, et al. Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the BREXIT study. Circulation. 2023;147(7):532–45. https://doi.org/10.1161/circulationaha.122.062814. Exercise performance and cardiac reserve improved in early stage breast cancer patients compared to usual care after 12 months of training.CrossRefPubMed

66.

Jones LW, Douglas PS, Khouri MG, Mackey JR, Wojdyla D, Kraus WE, et al. Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial. J Clin Oncol. 2014;32(23):2496–502. https://doi.org/10.1200/jco.2013.53.5724.CrossRefPubMedPubMedCentral

67.

Scott JM, Zabor EC, Schwitzer E, Koelwyn GJ, Adams SC, Nilsen TS, et al. Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol. 2018;36(22):2297–305. https://doi.org/10.1200/jco.2017.77.5809.CrossRefPubMedPubMedCentral

68.

Lee K, Tripathy D, Demark-Wahnefried W, Courneya KS, Sami N, Bernstein L, et al. Effect of aerobic and resistance exercise intervention on cardiovascular disease risk in women with early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2019;5(5):710–4. https://doi.org/10.1001/jamaoncol.2019.0038.CrossRefPubMedPubMedCentral

69.

Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Friedenreich CM, Yasui Y, et al. Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J Natl Cancer Inst. 2013;105(23):1821–32. https://doi.org/10.1093/jnci/djt297.CrossRefPubMed

70.

Kerrigan DJ, Reddy M, Walker EM, Cook B, McCord J, Loutfi R, et al. Cardiac rehabilitation improves fitness in patients with subclinical markers of cardiotoxicity while receiving chemotherapy: a randomized controlled study. J Cardiopulm Rehabil Prev. 2023;43(2):129–34. https://doi.org/10.1097/hcr.0000000000000719.CrossRefPubMed

71.

Mijwel S, Jervaeus A, Bolam KA, Norrbom J, Bergh J, Rundqvist H, et al. High-intensity exercise during chemotherapy induces beneficial effects 12 months into breast cancer survivorship. J Cancer Surviv. 2019;13(2):244–56. https://doi.org/10.1007/s11764-019-00747-z.CrossRefPubMedPubMedCentral

72.

Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Buchanan TA, et al. Effects of aerobic and resistance exercise on metabolic syndrome, sarcopenic obesity, and circulating biomarkers in overweight or obese survivors of breast cancer: a randomized controlled trial. J Clin Oncol. 2018;36(9):875–83. https://doi.org/10.1200/jco.2017.75.7526.CrossRefPubMedPubMedCentral

73.

Sturgeon KM, Brown JC, Sears DD, Sarwer DB, Schmitz KH. WISER survivor trial: combined effect of exercise and weight loss interventions on inflammation in breast cancer survivors. Med Sci Sports Exerc. 2023;55(2):209–15. https://doi.org/10.1249/mss.0000000000003050.CrossRefPubMed

74.

Ndjavera W, Orange ST, O’Doherty AF, Leicht AS, Rochester M, Mills R, et al. Exercise-induced attenuation of treatment side-effects in patients with newly diagnosed prostate cancer beginning androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2020;125(1):28–37. https://doi.org/10.1111/bju.14922.CrossRefPubMed

75.

Wall BA, GalvãO DA, Fatehee N, Taaffe DR, Spry N, Joseph D, et al. Exercise improves V˙O2max and body composition in androgen deprivation therapy-treated prostate cancer patients. Med Sci Sports Exerc. 2017;49(8):1503–10. https://doi.org/10.1249/mss.0000000000001277.CrossRefPubMed

76.

Rueegg CS, Zürcher SJ, Schindera C, Jung R, Deng WH, Bänteli I, et al. Effect of a 1-year physical activity intervention on cardiovascular health in long-term childhood cancer survivors-a randomised controlled trial (SURfit). Br J Cancer. 2023;129(8):1284–97. https://doi.org/10.1038/s41416-023-02410-y.CrossRefPubMed

77.

Gilbert SE, Tew GA, Fairhurst C, Bourke L, Saxton JM, Winter EM, et al. Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer. Br J Cancer. 2016;114(4):401–8. https://doi.org/10.1038/bjc.2015.479.CrossRefPubMedPubMedCentral

78.

Lee K, Kang I, Mack WJ, Mortimer J, Sattler F, Salem G, et al. Effects of high-intensity interval training on vascular endothelial function and vascular wall thickness in breast cancer patients receiving anthracycline-based chemotherapy: a randomized pilot study. Breast Cancer Res Treat. 2019;177(2):477–85. https://doi.org/10.1007/s10549-019-05332-7.CrossRefPubMedPubMedCentral

79.

Sebio Garcia R, Yáñez Brage MI, Giménez Moolhuyzen E, Granger CL, Denehy L. Functional and postoperative outcomes after preoperative exercise training in patients with lung cancer: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2016;23(3):486–97. https://doi.org/10.1093/icvts/ivw152.CrossRefPubMed

80.

Yang L, Morielli AR, Heer E, Kirkham AA, Cheung WY, Usmani N, et al. Effects of exercise on cancer treatment efficacy: a systematic review of preclinical and clinical studies. Cancer Res. 2021;81(19):4889–95. https://doi.org/10.1158/0008-5472.Can-21-1258.CrossRefPubMedPubMedCentral

81.

Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006;24(22):3535–41. https://doi.org/10.1200/jco.2006.06.0863.CrossRefPubMed

82.

Morishita S, Hamaue Y, Fukushima T, Tanaka T, Fu JB, Nakano J. Effect of exercise on mortality and recurrence in patients with cancer: a systematic review and meta-analysis. Integr Cancer Ther. 2020;19:1534735420917462. https://doi.org/10.1177/1534735420917462.CrossRefPubMedPubMedCentral

83.

Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry WT, et al. Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. Cancer Prev Res (Phila). 2013;6(9):925–37. https://doi.org/10.1158/1940-6207.Capr-12-0416.CrossRefPubMed

84.

Hayes SCSM, Spence R, Pyke C, Saunders C, Bashford J, Eakin E. Can exercise influence survival following breast cancer: results from a randomised, controlled trial. J Clin Oncol. 2017;35:S10067-S. https://doi.org/10.1200/JCO.2017.35.15_suppl.10067.CrossRef

85.

Jones LW, Habel LA, Weltzien E, Castillo A, Gupta D, Kroenke CH, et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J Clin Oncol. 2016;34(23):2743–9. https://doi.org/10.1200/jco.2015.65.6603.CrossRefPubMedPubMedCentral

86.

Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 2015;33(10):1104–11. https://doi.org/10.1200/jco.2014.57.1547.CrossRefPubMed

87.

Zimmer P, Baumann FT, Oberste M, Schmitt J, Joisten N, Hartig P, et al. Influence of personalized exercise recommendations during rehabilitation on the sustainability of objectively measured physical activity levels, fatigue, and fatigue-related biomarkers in patients with breast cancer. Integr Cancer Ther. 2018;17(2):306–11. https://doi.org/10.1177/1534735417713301.CrossRefPubMed

88.

Schultz EB, Zubac D, Bloch W, Baurecht H, Rickert J, Baumann FT. Moderate intensity exercise reduces side effects of cancer therapy and maintains cardiorespiratory fitness in male breast cancer patients: findings from the BRECA male crossover study. Breast Care (Basel). 2023;18(6):483–92. https://doi.org/10.1159/000534090.CrossRefPubMed

89.

Wernhart S, Rassaf T. Exercise, cancer, and the cardiovascular system: clinical effects and mechanistic insights. Basic Res Cardiol. 2024. https://doi.org/10.1007/s00395-024-01034-4.CrossRefPubMed

90.

Hiensch AE, Monninkhof EM, Schmidt ME, Zopf EM, Bolam KA, Aaronson NK, et al. Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: the EFFECT study. Trials. 2022;23(1):610. https://doi.org/10.1186/s13063-022-06556-7.CrossRefPubMedPubMedCentral

91.

Bauer J, Morley JE, Schols A, Ferrucci L, Cruz-Jentoft AJ, Dent E, et al. Sarcopenia: a time for action An SCWD Position Paper. J Cachexia Sarcopenia Muscle. 2019;10(5):956–61. https://doi.org/10.1002/jcsm.12483.CrossRefPubMedPubMedCentral

92.

Anker MS, Lena A, Roeland EJ, Porthun J, Schmitz S, Hadzibegovic S, et al. Patient-reported ability to walk 4 m and to wash: new clinical endpoints and predictors of survival in patients with pre-terminal cancer. J Cachexia Sarcopenia Muscle. 2023;14(4):1670–81. https://doi.org/10.1002/jcsm.13247.CrossRefPubMedPubMedCentral

93.

Hadzibegovic S, Porthun J, Lena A, Weinländer P, Lück LC, Potthoff SK, et al. Hand grip strength in patients with advanced cancer: a prospective study. J Cachexia Sarcopenia Muscle. 2023;14(4):1682–94. https://doi.org/10.1002/jcsm.13248.CrossRefPubMedPubMedCentral

94.

Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17–96. https://doi.org/10.1093/eurheartj/ehaa605.CrossRefPubMed

95.

Porter C, Reidy PT, Bhattarai N, Sidossis LS, Rasmussen BB. Resistance exercise training alters mitochondrial function in human skeletal muscle. Med Sci Sports Exerc. 2015;47(9):1922–31. https://doi.org/10.1249/mss.0000000000000605.CrossRefPubMedPubMedCentral

96.

McDonald J, Sayers J, Anker SD, Arends J, Balstad TR, Baracos V, et al. Physical function endpoints in cancer cachexia clinical trials: systematic review 1 of the cachexia endpoints series. J Cachexia Sarcopenia Muscle. 2023;14(5):1932–48. https://doi.org/10.1002/jcsm.13321.CrossRefPubMedPubMedCentral

97.

Strasser B, Steindorf K, Wiskemann J, Ulrich CM. Impact of resistance training in cancer survivors: a meta-analysis. Med Sci Sports Exerc. 2013;45(11):2080–90. https://doi.org/10.1249/MSS.0b013e31829a3b63.CrossRefPubMed

98.

Antunes JMM, Ferreira RMP, Moreira-Gonçalves D. Exercise training as therapy for cancer-induced cardiac cachexia. Trends Mol Med. 2018;24(8):709–27. https://doi.org/10.1016/j.molmed.2018.06.002.CrossRefPubMed

99.

Foulkes SJ, Haykowsky MJ, Li T, Wang J, Kennedy M, Kirkham AA, et al. Determinants of impaired peak oxygen uptake in breast cancer survivors: JACC: CardioOncology Primer. JACC CardioOncol. 2024;6(1):33–7. https://doi.org/10.1016/j.jaccao.2023.11.005.CrossRefPubMed

100.

Milanović Z, Sporiš G, Weston M. Effectiveness of high-intensity interval training (HIT) and continuous endurance training for VO2max improvements: a systematic review and meta-analysis of controlled trials. Sports Med. 2015;45(10):1469–81. https://doi.org/10.1007/s40279-015-0365-0.CrossRefPubMed

101.

Wisløff U, Støylen A, Loennechen JP, Bruvold M, Rognmo Ø, Haram PM, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation. 2007;115(24):3086–94. https://doi.org/10.1161/circulationaha.106.675041.CrossRefPubMed

102.

Ellingsen Ø, Halle M, Conraads V, Støylen A, Dalen H, Delagardelle C, et al. High-intensity interval training in patients with heart failure with reduced ejection fraction. Circulation. 2017;135(9):839–49. https://doi.org/10.1161/circulationaha.116.022924.CrossRefPubMedPubMedCentral

103.

Mueller S, Winzer EB, Duvinage A, Gevaert AB, Edelmann F, Haller B, et al. Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2021;325(6):542–51. https://doi.org/10.1001/jama.2020.26812.CrossRefPubMedPubMedCentral

104.

Siddiqi TJ, Rashid AM, Javaid SS, Siddiqi AK, Usman MS, Hervir O, et al. High-intensity interval training versus moderate continuous training in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48(8):101720. https://doi.org/10.1016/j.cpcardiol.2023.101720.CrossRefPubMed

105.

Gomes Neto M, Durães AR, Conceição LSR, Saquetto MB, Ellingsen Ø, Carvalho VO. High intensity interval training versus moderate intensity continuous training on exercise capacity and quality of life in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis. Int J Cardiol. 2018;261:134–41. https://doi.org/10.1016/j.ijcard.2018.02.076.CrossRefPubMed

106.

Haykowsky MJ, Timmons MP, Kruger C, McNeely M, Taylor DA, Clark AM. Meta-analysis of aerobic interval training on exercise capacity and systolic function in patients with heart failure and reduced ejection fractions. Am J Cardiol. 2013;111(10):1466–9. https://doi.org/10.1016/j.amjcard.2013.01.303.CrossRefPubMed

107.

Wallen MP, Hennessy D, Brown S, Evans L, Rawstorn JC, Wong Shee A, et al. High-intensity interval training improves cardiorespiratory fitness in cancer patients and survivors: a meta-analysis. Eur J Cancer Care (Engl). 2020;29(4):e13267. https://doi.org/10.1111/ecc.13267.CrossRefPubMed

108.

Adams SC, DeLorey DS, Davenport MH, Stickland MK, Fairey AS, North S, et al. Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: a phase 2 randomized controlled trial. Cancer. 2017;123(20):4057–65. https://doi.org/10.1002/cncr.30859.CrossRefPubMed

109.

Isanejad A, Nazari S, Gharib B, Motlagh AG. Comparison of the effects of high-intensity interval and moderate-intensity continuous training on inflammatory markers, cardiorespiratory fitness, and quality of life in breast cancer patients. J Sport Health Sci. 2023;12(6):674–89. https://doi.org/10.1016/j.jshs.2023.07.001.CrossRefPubMedPubMedCentral

110.

Toohey K, Pumpa K, McKune A, Cooke J, Welvaert M, Northey J, et al. The impact of high-intensity interval training exercise on breast cancer survivors: a pilot study to explore fitness, cardiac regulation and biomarkers of the stress systems. BMC Cancer. 2020;20(1):787. https://doi.org/10.1186/s12885-020-07295-1.CrossRefPubMedPubMedCentral

111.

Adams SC, DeLorey DS, Davenport MH, Fairey AS, North S, Courneya KS. Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors. Br J Cancer. 2018;118(10):1313–21. https://doi.org/10.1038/s41416-018-0044-7.CrossRefPubMedPubMedCentral

112.

Herranz-Gómez A, Cuenca-Martínez F, Suso-Martí L, Varangot-Reille C, Calatayud J, Blanco-Díaz M, et al. Effectiveness of HIIT in patients with cancer or cancer survivors: an umbrella and mapping review with meta-meta-analysis. Scand J Med Sci Sports. 2022;32(11):1522–49. https://doi.org/10.1111/sms.14223.CrossRefPubMedPubMedCentral

113.

Kang DW, Wilson RL, Christopher CN, Normann AJ, Barnes O, Lesansee JD, et al. Exercise cardio-oncology: exercise as a potential therapeutic modality in the management of anthracycline-induced cardiotoxicity. Front Cardiovasc Med. 2021;8:805735. https://doi.org/10.3389/fcvm.2021.805735.CrossRefPubMed

114.

Shephard RJ, Balady GJ. Exercise as cardiovascular therapy. Circulation. 1999;99(7):963–72. https://doi.org/10.1161/01.cir.99.7.963.CrossRefPubMed

115.

Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun. 2004;313(3):459–65. https://doi.org/10.1016/j.bbrc.2003.11.136.CrossRefPubMed

116.

Attaix D, Ventadour S, Codran A, Béchet D, Taillandier D, Combaret L. The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem. 2005;41:173–86. https://doi.org/10.1042/eb0410173.CrossRefPubMed

117.

Rodriguez J, Vernus B, Chelh I, Cassar-Malek I, Gabillard JC, Hadj Sassi A, et al. Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. Cell Mol Life Sci. 2014;71(22):4361–71. https://doi.org/10.1007/s00018-014-1689-x.CrossRefPubMed

118.

Zong WX, Rabinowitz JD, White E. Mitochondria and cancer. Mol Cell. 2016;61(5):667–76. https://doi.org/10.1016/j.molcel.2016.02.011.CrossRefPubMedPubMedCentral

119.

Laker RC, Drake JC, Wilson RJ, Lira VA, Lewellen BM, Ryall KA, et al. Ampk phosphorylation of Ulk1 is required for targeting of mitochondria to lysosomes in exercise-induced mitophagy. Nat Commun. 2017;8(1):548. https://doi.org/10.1038/s41467-017-00520-9.CrossRefPubMedPubMedCentral

120.

White E, Mehnert JM, Chan CS. Autophagy, metabolism, and cancer. Clin Cancer Res. 2015;21(22):5037–46. https://doi.org/10.1158/1078-0432.Ccr-15-0490.CrossRefPubMedPubMedCentral

121.

Cunha TF, Bacurau AV, Moreira JB, Paixão NA, Campos JC, Ferreira JC, et al. Exercise training prevents oxidative stress and ubiquitin-proteasome system overactivity and reverse skeletal muscle atrophy in heart failure. PLoS ONE. 2012;7(8):e41701. https://doi.org/10.1371/journal.pone.0041701.CrossRefPubMedPubMedCentral

122.

Gielen S, Sandri M, Kozarez I, Kratzsch J, Teupser D, Thiery J, et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation. 2012;125(22):2716–27. https://doi.org/10.1161/circulationaha.111.047381.CrossRefPubMed

123.

Lenk K, Erbs S, Höllriegel R, Beck E, Linke A, Gielen S, et al. Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure. Eur J Prev Cardiol. 2012;19(3):404–11. https://doi.org/10.1177/1741826711402735.CrossRefPubMed

124.

Wei X, Liu X, Rosenzweig A. What do we know about the cardiac benefits of exercise? Trends Cardiovasc Med. 2015;25(6):529–36. https://doi.org/10.1016/j.tcm.2014.12.014.CrossRefPubMed

125.

Agostini D, Natalucci V, Baldelli G, De Santi M, Donati Zeppa S, Vallorani L, et al. New insights into the role of exercise in inhibiting mTOR signaling in triple-negative breast cancer. Oxid Med Cell Longev. 2018;2018:5896786. https://doi.org/10.1155/2018/5896786.CrossRefPubMedPubMedCentral

126.

Leung PS, Aronson WJ, Ngo TH, Golding LA, Barnard RJ. Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumor cells in vitro. J Appl Physiol (1985). 2004;96(2):450–4. https://doi.org/10.1152/japplphysiol.00871.2003.

127.

Vega RB, Konhilas JP, Kelly DP, Leinwand LA. Molecular mechanisms underlying cardiac adaptation to exercise. Cell Metab. 2017;25(5):1012–26. https://doi.org/10.1016/j.cmet.2017.04.025.CrossRefPubMedPubMedCentral

128.

Linke A, Adams V, Schulze PC, Erbs S, Gielen S, Fiehn E, et al. Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle. Circulation. 2005;111(14):1763–70. https://doi.org/10.1161/01.Cir.0000165503.08661.E5.CrossRefPubMed

129.

Souza RW, Fernandez GJ, Cunha JP, Piedade WP, Soares LC, Souza PA, et al. Regulation of cardiac microRNAs induced by aerobic exercise training during heart failure. Am J Physiol Heart Circ Physiol. 2015;309(10):H1629–41. https://doi.org/10.1152/ajpheart.00941.2014.CrossRefPubMed

130.

Landers-Ramos RQ, Sapp RM, Jenkins NT, Murphy AE, Cancre L, Chin ER, et al. Chronic endurance exercise affects paracrine action of CD31+ and CD34+ cells on endothelial tube formation. Am J Physiol Heart Circ Physiol. 2015;309(3):H407–20. https://doi.org/10.1152/ajpheart.00123.2015.CrossRefPubMedPubMedCentral

131.

Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev. 2008;88(2):611–38. https://doi.org/10.1152/physrev.00025.2007.CrossRefPubMed

132.

de Souza PA, de Souza RW, Soares LC, Piedade WP, Campos DH, Carvalho RF, et al. Aerobic training attenuates nicotinic acethylcholine receptor changes in the diaphragm muscle during heart failure. Histol Histopathol. 2015;30(7):801–11. https://doi.org/10.14670/hh-11-581.CrossRefPubMed

133.

Hambrecht R, Fiehn E, Yu J, Niebauer J, Weigl C, Hilbrich L, et al. Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J Am Coll Cardiol. 1997;29(5):1067–73. https://doi.org/10.1016/s0735-1097(97)00015-6.CrossRefPubMed

134.

Irrcher I, Ljubicic V, Hood DA. Interactions between ROS and AMP kinase activity in the regulation of PGC-1alpha transcription in skeletal muscle cells. Am J Physiol Cell Physiol. 2009;296(1):C116–23. https://doi.org/10.1152/ajpcell.00267.2007.CrossRefPubMed

135.

Gaude E, Frezza C. Defects in mitochondrial metabolism and cancer. Cancer Metab. 2014;2:10. https://doi.org/10.1186/2049-3002-2-10.CrossRefPubMedPubMedCentral

136.

Kim Y, Triolo M, Erlich AT, Hood DA. Regulation of autophagic and mitophagic flux during chronic contractile activity-induced muscle adaptations. Pflugers Arch. 2019;471(3):431–40. https://doi.org/10.1007/s00424-018-2225-x.CrossRefPubMed

137.

Liu Y, Sun Y, Guo Y, Shi X, Chen X, Feng W, et al. An overview: the diversified role of mitochondria in cancer metabolism. Int J Biol Sci. 2023;19(3):897–915. https://doi.org/10.7150/ijbs.81609.CrossRefPubMedPubMedCentral

138.

Van Craenenbroeck EM, Frederix G, Pattyn N, Beckers P, Van Craenenbroeck AH, Gevaert A, et al. Effects of aerobic interval training and continuous training on cellular markers of endothelial integrity in coronary artery disease: a SAINTEX-CAD substudy. Am J Physiol Heart Circ Physiol. 2015;309(11):H1876–82. https://doi.org/10.1152/ajpheart.00341.2015.CrossRefPubMed

139.

Hasenfuss G, Reinecke H, Studer R, Meyer M, Pieske B, Holtz J, et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res. 1994;75(3):434–42. https://doi.org/10.1161/01.res.75.3.434.CrossRefPubMed

140.

Wisløff U, Loennechen JP, Falck G, Beisvag V, Currie S, Smith G, et al. Increased contractility and calcium sensitivity in cardiac myocytes isolated from endurance trained rats. Cardiovasc Res. 2001;50(3):495–508. https://doi.org/10.1016/s0008-6363(01)00210-3.CrossRefPubMed

141.

Kemi OJ, Ellingsen O, Ceci M, Grimaldi S, Smith GL, Condorelli G, et al. Aerobic interval training enhances cardiomyocyte contractility and Ca2+ cycling by phosphorylation of CaMKII and Thr-17 of phospholamban. J Mol Cell Cardiol. 2007;43(3):354–61. https://doi.org/10.1016/j.yjmcc.2007.06.013.CrossRefPubMedPubMedCentral

142.

Waring CD, Vicinanza C, Papalamprou A, Smith AJ, Purushothaman S, Goldspink DF, et al. The adult heart responds to increased workload with physiologic hypertrophy, cardiac stem cell activation, and new myocyte formation. Eur Heart J. 2014;35(39):2722–31. https://doi.org/10.1093/eurheartj/ehs338.CrossRefPubMed

143.

Uth J, Fristrup B, Sørensen V, Helge EW, Christensen MK, Kjærgaard JB, et al. Exercise intensity and cardiovascular health outcomes after 12 months of football fitness training in women treated for stage I-III breast cancer: results from the football fitness After Breast Cancer (ABC) randomized controlled trial. Prog Cardiovasc Dis. 2020;63(6):792–9. https://doi.org/10.1016/j.pcad.2020.08.002.CrossRefPubMed

144.

MacInnis MJ, Gibala MJ. Physiological adaptations to interval training and the role of exercise intensity. J Physiol. 2017;595(9):2915–30. https://doi.org/10.1113/jp273196.CrossRefPubMed

145.

Zucker IH, Musch TI. Benefits of exercise training on cardiovascular dysfunction: molecular and integrative. Am J Physiol Heart Circ Physiol. 2018;315(4):H1027–31. https://doi.org/10.1152/ajpheart.00516.2018.CrossRefPubMed

146.

Burgomaster KA, Howarth KR, Phillips SM, Rakobowchuk M, Macdonald MJ, McGee SL, et al. Similar metabolic adaptations during exercise after low volume sprint interval and traditional endurance training in humans. J Physiol. 2008;586(1):151–60. https://doi.org/10.1113/jphysiol.2007.142109.CrossRefPubMed

147.

Coffey VG, Hawley JA. The molecular bases of training adaptation. Sports Med. 2007;37(9):737–63. https://doi.org/10.2165/00007256-200737090-00001.CrossRefPubMed

148.

Little JP, Safdar A, Bishop D, Tarnopolsky MA, Gibala MJ. An acute bout of high-intensity interval training increases the nuclear abundance of PGC-1α and activates mitochondrial biogenesis in human skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2011;300(6):R1303–10. https://doi.org/10.1152/ajpregu.00538.2010.CrossRefPubMed

149.

Tjønna AE, Leinan IM, Bartnes AT, Jenssen BM, Gibala MJ, Winett RA, et al. Low- and high-volume of intensive endurance training significantly improves maximal oxygen uptake after 10-weeks of training in healthy men. PLoS ONE. 2013;8(5):e65382. https://doi.org/10.1371/journal.pone.0065382.CrossRefPubMedPubMedCentral

150.

Montero D, Diaz-Cañestro C, Lundby C. Endurance training and V˙O2max: role of maximal cardiac output and oxygen extraction. Med Sci Sports Exerc. 2015;47(10):2024–33. https://doi.org/10.1249/mss.0000000000000640.CrossRefPubMed

151.

Wernhart S, Papathanasiou M, Mahabadi AA, Rassaf T, Luedike P. Betablockers reduce oxygen pulse increase and performance in heart failure patients with preserved ejection fraction. Int J Cardiol. 2023;370:309–18. https://doi.org/10.1016/j.ijcard.2022.10.009.CrossRefPubMed

152.

Wernhart S, Papathanasiou M, Rassaf T, Luedike P. The controversial role of beta-blockers in heart failure with preserved ejection fraction. Pharmacol Ther. 2023;243:108356. https://doi.org/10.1016/j.pharmthera.2023.108356.CrossRefPubMed

153.

Adams V, Reich B, Uhlemann M, Niebauer J. Molecular effects of exercise training in patients with cardiovascular disease: focus on skeletal muscle, endothelium, and myocardium. Am J Physiol Heart Circ Physiol. 2017;313(1):H72-h88. https://doi.org/10.1152/ajpheart.00470.2016.CrossRefPubMed

154.

La Gerche A, Howden EJ, Haykowsky MJ, Lewis GD, Levine BD, Kovacic JC. Heart failure with preserved ejection fraction as an exercise deficiency syndrome: JACC Focus Seminar 2/4. J Am Coll Cardiol. 2022;80(12):1177–91. https://doi.org/10.1016/j.jacc.2022.07.011.CrossRefPubMed

155.

Tsai E, Mouhayar E, Lenihan D, Song J, Durand JB, Fadol A, et al. Feasibility and outcomes of an exercise intervention for chemotherapy-induced heart failure. J Cardiopulm Rehabil Prev. 2019;39(3):199–203. https://doi.org/10.1097/hcr.0000000000000388.CrossRefPubMedPubMedCentral

156.

Viamonte SG, Joaquim A, Alves A, Vilela E, Capela A, Ferreira C, et al. Adherence, safety, and satisfaction of a cardio-oncology rehabilitation program framework versus community exercise training for cancer survivors: findings from the CORE trial. Support Care Cancer. 2023;31(3):173. https://doi.org/10.1007/s00520-023-07638-1.CrossRefPubMedPubMedCentral

157.

Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D, et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8(1):33–40. https://doi.org/10.1161/circheartfailure.114.001615.CrossRefPubMed

158.

Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, et al. Dose-response relationship between physical activity and risk of heart failure: a meta-analysis. Circulation. 2015;132(19):1786–94. https://doi.org/10.1161/circulationaha.115.015853.CrossRefPubMed

159.

Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation. 2019;139(21):e997–1012. https://doi.org/10.1161/cir.0000000000000679.CrossRefPubMedPubMedCentral

160.

Lakoski SG, Eves ND, Douglas PS, Jones LW. Exercise rehabilitation in patients with cancer. Nat Rev Clin Oncol. 2012;9(5):288–96. https://doi.org/10.1038/nrclinonc.2012.27.CrossRefPubMedPubMedCentral

161.

Pituskin E, Cox-Kennett N, Foulkes S, Driga A, Dimitry R, Thompson RB, et al. Cardio-oncology and cancer rehabilitation: is an integrated approach possible? Can J Cardiol. 2023. https://doi.org/10.1016/j.cjca.2023.09.024.CrossRefPubMed

162.

Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, et al. Onco-cardiology: consensus paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol. 2020;109(10):1197–222. https://doi.org/10.1007/s00392-020-01636-7.CrossRefPubMedPubMedCentral

Title: Relevance of Cardiovascular Exercise in Cancer and Cancer Therapy-Related Cardiac Dysfunction
Authors: Simon Wernhart
Tienush Rassaf
Publication date: 02-05-2024
Publisher: Springer US
Keywords: Heart Failure
Cancer Therapy
Published in: Current Heart Failure Reports / Issue 3/2024
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-024-00662-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of the Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2024

Evaluation and Management of Hyponatremia in Heart Failure

Putting More Weight on Obesity Trials in Heart Failure

Pregnancy, Reproductive Factors, and Female Heart Failure Risk and Outcomes

Non-Coding Ribonucleic Acids as Diagnostic and Therapeutic Targets in Cardiac Fibrosis

Catheter Ablation of Ventricular Tachycardia in Ischemic Heart Disease: What Is Known and New Perspectives

Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials